Androgen deprivation therapy in prostate cancer: Focusing on sexual side effects

Journal of Sexual Medicine

Volumn 9, Issue 3, 2012, Pages 887-902

  Corona, Giovanni ^a,b   Gacci, Mauro ^a   Baldi, Elisabetta ^a   Mancina, Rosa ^a   Forti, Gianni ^a   Maggi, Mario ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Azienda USL di Bologna   (Italy)

Author keywords

Androgen deprivation therapy; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANOLONE; BICALUTAMIDE; DUTASTERIDE; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LIPOPROTEIN; METRIBOLONE; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RISK; CARDIOVASCULAR RISK; CASTRATION; CASTRATION RESISTANT PROSTATE CANCER; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; EJACULATION DISORDER; EJACULATORY DUCT; ERECTILE DYSFUNCTION; HAIR LOSS; HOT FLUSH; HUMAN; HYPOACTIVE SEXUAL DESIRE DISORDER; INSULIN SENSITIVITY; LIBIDO DISORDER; LIPOPROTEIN BLOOD LEVEL; LYMPH NODE METASTASIS; META ANALYSIS (TOPIC); NONHUMAN; OBESITY; ORCHIECTOMY; ORGASM DISORDER; OVERALL SURVIVAL; PENIS ERECTION; PENIS NOCTURNAL TUMESCENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SHORT COURSE THERAPY; SURVIVAL TIME; UNSPECIFIED SIDE EFFECT;

EID: 84857654914     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02590.x     Document Type: Article

References (112)

1. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of PC and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
2. Malvezzi M, Arfé A, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2011. Ann Oncol 2011;22:947-56.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
4. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83.
5. Corona G, Baldi E, Maggi M. Androgen regulation of prostate cancer: Where are we now? J Endocrinol Invest 2011;34:232-43.
6. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-21.
7. Crescioli C, Feruzzi P, Caporali A, Mancina R, Comerci A, Muratori M, Scaltriti M, Vannelli GB, Smiroldo S, Mariani R, Villari D, Bettuzzi S, Serio M, Adorini L, Maggi M. Inhibition of spontaneous androgen-induced prostate growth by non hypercalcemic calcitriol analog. Endocrinology 2003;144:3046-57.
8. Wright AS, Douglas RC, Thomas LN, Lazier CB, Rittmaster RS. Androgen-induced regrowth in the castrated rat ventral prostate: Role of 5alpha-reductase. Endocrinology 1999;140:4509-15.
9. Corona G, Boddi V, Lotti F, Gacci M, Carini M, De Vita G, Sforza A, Forti G, Mannucci E, Maggi M. The relationship of testosterone to prostate-specific antigen in men with sexual dysfunction. J Sex Med 2010;7(Pt 1):284-92.
10. Gacci M, Corona G, Apolone G, Lanciotti M, Tosi N, Giancane S, Masieri L, Serni S, Maggi M, Carini M. Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. Prostate Cancer Prostatic Dis 2010;13:168-72.
11. Takizawa I, Nishiyama T, Hara N, Isahaya E, Hoshii T, Takahashi K. Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu. Prostate 2010;70:1395-401.
12. Smith MR. Androgen deprivation therapy for prostate cancer: New concepts and concerns. Curr Opin Endocrinol Diabetes Obes 2007;14:247-54.
13. Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009;181:1998-2008.
14. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006;4:CD006019.
15. Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, Wilt TJ, Aronson N. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 2002;95:361-76.
16. No author listed. Prostate Cancer Trialists' Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355:1491-8.
17. Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial-Casodex Combination Study Group. Urology 1997;50:330-6.
18. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev 2002;1:CD003506.
19. Schröder FH, Kurth KH, Fosså SD, Hoekstra W, Karthaus PP, Debois M, Collette L, Members of the European Organisation for the Research and Treatment of Cancer Genito-Urinary Group. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: Results of European Organisation for the Research and Treatment of Cancer 30846-A phase III study. J Urol 2004;172:923-7.
20. Schröder FH, Kurth KH, Fossa SD, Hoekstra W, Karthaus PP, De Prijck L, Collette L. Early versus delayed endocrine treatment of t2-t3 pn1-3 m0 prostate cancer without local treatment of the primary tumour: Final results of European organisation for the research and treatment of cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009;55:14-22.
21. Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011;365:107-18.
22. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, Bouffioux C, Coppens L, Bonnet P, Andrianne R, Wlatregny D. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormonenaive prostate cancer: Results of a prospective randomized multicenter trial. Clin Prostate Cancer 2002;1:163-71.
23. Abrahamsson PA. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 2010;57:49-59.
24. Raynaud JP. Prostate cancer risk in testosterone-treated men. J Steroid Biochem Mol Biol 2006;102:261-6.
25. Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 2009;1155:43-56.
26. Gravas S, Oelke M. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol 2010;28:9-15.
27. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of PC. N Engl J Med 2003;349:215-24.
28. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
29. Strope SA, Andriole GL. Update on chemoprevention for prostate cancer. Curr Opin Urol 2010;20:194-7.
30. Walsh PC. Chemoprevention of prostate cancer. N Engl J Med 2010;362:1237-8.
31. Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920-2.
32. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-6.
33. Davilla H, Arison C, Hall M, Salup R, Lockhart J, Carrion R. Analysis of the PSA response after testosterone supplementation in patients who previously received management for their localized prostate cancer. J Urol 2008;179(suppl 4):428, abstract 1247.
34. Nabulsi O, Tal R, Gotto G, Narus J, Goldenberg L, Mulhall JP. Outcomes analysis of testosterone supplementation in hypogonadal men following radical prostatectomy. J Urol 2008;179(suppl 4):406, abstract 1244.
35. Khera M, Grober ED, Najari B, Colen JS, Mohamed O, Lamb DJ, Lipshultz LI. Testosterone replacement therapy following radical prostatectomy. J Sex Med 2009;6:1165-70.
36. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int 2010;105:1397-401.
37. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: Preliminary observations. BJU Int 2009;103:62-4.
38. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer 2007;109:536-41.
39. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol 2011;185:1256-61.
40. Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC, International Society of Andrology (ISA), International Society for the Study of Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), American Society of Andrology (ASA). Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Int J Androl 2009;32:1-10.
41. Brendler H, Chase WE, Scott WW. Prostatic cancer: Further investigation of hormone relationships. Arch Surg 1950;61:433-40.
42. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009;56:237-44.
43. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-103.
44. Drewa T, Chlosta P. Re: Michael J. Morris, Daisy Huang, William K. Kelly etal. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol 2009;56:237-44. Eur Urol 2010;57:e18-9.
45. Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042-9.
46. Basaria S. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. J Androl 2008;29:534-9.
47. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C. Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol 2009;55:62-75.
48. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N, American Heart Association Council on Clinical Cardiology and Council on Epidemiology and Prevention, American Cancer Society, American Urological Association. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: A science advisory from the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833-40.
49. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E, Maggi M. Hypogonadism as a risk factor for cardiovascular mortality in men: A meta-analytic study. Eur J Endocrinol 2011;165:276-85.
50. Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002;56:779-86.
51. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001;86:4261-7.
52. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
53. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
54. Chen Z, Maricic M, Nguyen P, Ahmann FR, Bruhn R, Dalkin BL. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer 2002;95:2136-44.
55. Lee H, McGovern K, Finkelstein J, Smith MR. Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005;104:1633-7.
56. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003;104:195-201.
57. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen deprivation therapy. Cancer 2006;106:581-8.
58. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
59. Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res 2006;18:494-8.
60. Studer UE, Whelan P, Albrecht W, Casselman J, Dereijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868-76.
61. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
62. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A, Kantoff PW. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
63. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
64. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 2008;54:816-23.
65. Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610. J Clin Oncol 2008;26:585.
66. Nanda A, Chen MH, Braccioforte MH, Moran BJ, D'Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 2009;302:866-73.
67. Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009;27:92.
68. Hayes JH, Chen MH, Moran BJ, Braccioforte MH, Dosoretz DE, Salenius S, Katin MJ, Ross R, Choueiri TK, D'Amico AV. Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke. BJU Int 2010;106:979-85.
69. Keating NL, O'Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39-46.
70. Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, Grossmann M. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011;74:377-83.
71. Mohamedali HZ, Breunis H, Timilshina N, Alibhai SM. Changes in blood glucose and cholesterol levels due to androgen deprivation therapy in men with non-metastatic prostate cancer. Can Urol Assoc J 2011;5:28-32.
72. Rochira V, Zirilli L, Madeo B, Balestrieri A, Granata AR, Carani C. Sex steroids and sexual desire mechanism. J Endocrinol Invest 2003;26:29-36.
73. Vignozzi L, Corona G, Petrone L, Filippi S, Morelli AM, Forti G, Maggi M. Testosterone and sexual activity. J Endocrinol Invest 2005;28:39-44.
74. Heim N, Hursch CJ. Castration for sex offenders: Treatment or punishment? A review and critique of recent European literature. Arch Sex Behav 1979;8:281-304.
75. Kwan M, Greenleaf WJ, Mann J, Crapo L, Davidson JM. The nature of androgen action on male sexuality: A combined laboratory-self-report study on hypogonadal men. Clin Endocrinol Metab 1983;57:557-62.
76. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12:59-66.
77. Greenstein A, Plymate SR, Katz PG. Visually stimulated erection in castrated men. J Urol 1995;153:650-2.
78. Davidson JM. Androgen replacement therapy in a wider context: Clinical and basic aspects. In: Dennerstein L, Fraser I, eds. Hormones and behavior. New York: Elsevier Science Publishers; 1986:433-41.
79. Dettenhofer MH. Eunuchus, women and imperial courts. In: Sheidel W, ed. Rome and China: Comparative perspective ancient world empire. Oxford; New York: Oxford University Press; 2009:83-9.
80. Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB, Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology 2004;145:2253-63.
81. Zhang XH, Morelli A, Luconi M, Vignozzi L, Filippi S, Marini M, Vannelli GB, Mancina R, Forti G, Maggi M. Testosterone regulates PDE5 expression and in vivo responsiveness to tadalafil in rat corpus cavernosum. Eur Urol 2005;47:409-16.
82. Corona G, Maggi M. The role of testosterone in erectile dysfunction. Nat Rev Urol 2010;7:46-56.
83. Corona G, Petrone L, Mannucci E, Ricca V, Balercia G, Giommi R, Forti G, Maggi M. The impotent couple: Low desire. Int J Androl 2005;28(suppl 2):46-52.
84. Isidori AM, Giannetta E, Gianfrilli D, Greco EA, Bonifacio V, Aversa A, Isidori A, Fabbri A, Lenzi A. Effects of testosterone on sexual function in men: Results of a meta-analysis. Clin Endocrinol (Oxf) 2005;63:381-94.
85. Ellis WJ, Grayhack JT. Sexual function in aging males after orchidectomy and estrogen therapy. J Urol 1963;89:895-9.
86. Rousseau L, Dupont A, Labrie F, Couture M. Sexuality changes in prostate cancer patients receiving antihormonal therapy combining the antiandrogen flutamide with medical (LHRH agonist) or surgical castration. Arch Sex Behav 1988;17:87-98.
87. Marumo K, Baba S, Murai M. Erectile function and nocturnal penile tumescence in patients with prostate cancer undergoing luteinizing hormone-releasing hormone agonist therapy. Int J Urol 1999;6:19-23.
88. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7.
89. Fowler FJ Jr, McNaughton Collins M, Walker Corkery E, Elliott DB, Barry MJ. The impact of androgen deprivation on quality of life after radical prostatectomy for prostate carcinoma. Cancer 2002;95:287-95.
90. Watkins Bruner D, James JL, Bryan CJ, Pisansky TM, Rotman M, Corbett T, Speight J, Byhardt R, Sandler H, Bentzen S, Kachnic L, Berk L. Randomized, double-blinded, placebo-controlled crossover trial of treating erectile dysfunction with sildenafil after radiotherapy and short-term androgen deprivation therapy: Results of RTOG 0215. J Sex Med 2011;8:1228-38.
91. Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW, ADT Survivorship Working Group. Androgen deprivation therapy for prostate cancer: Recommendations to improve patient and partner quality of life. J Sex Med 2010;7:2996-3010.
92. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995;45:839-44.
93. Higano CS, Ellis W, Russell K, Lange PH. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 1996;48:800-4.
94. Bruchovsky N, Klotz L, Crook J, Phillips N, Abersbach J, Goldenberg SL. Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer 2008;6:46-52.
95. Khera M. Androgens and erectile function: A case for early androgen use in postprostatectomy hypogonadal men. J Sex Med 2009;6(suppl 3):234-8.
96. Vignozzi L, Filippi S, Morelli A, Marini M, Chavalmane A, Fibbi B, Silvestrini E, Mancina R, Carini M, Vannelli GB, Forti G, Maggi M. Cavernous neurotomy in the rat is associated with the onset of an overt condition of hypogonadism. J Sex Med 2009;6:1270-83.
97. Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K. Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006;42:1083-92.
98. Corona G, Mannucci E, Lotti F, Boddi V, Jannini EA, Fisher AD, Monami M, Sforza A, Forti G, Maggi M. Impairment of couple relationship in male patients with sexual dysfunction is associated with overt hypogonadism. J Sex Med 2009;6:2591-600.
99. Moinpour CM, Darke AK, Donaldson GW, Thompson IM Jr, Langley C, Ankerst DP, Patrick DL, Ware JE Jr, Ganz PA, Shumaker SA, Lippman SM, Coltman CA Jr. Longitudinal analysis of sexual function reported by men in the prostate cancer prevention trial. J Natl Cancer Inst 2007;99:1025-35.
100. Canguven O, Burnett AL. The effect of 5a-reductase inhibitors on erectile function. J Androl 2008;29:514-23.
101. Erdemir F, Harbin A, Hellstorm WJ. 5a reductase inhibitors and erectile dysfunction: The connection. J Sex Med 2008;5:2917-24.
102. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia: The finasteride study group. N Engl J Med 1992;327:1185-91.
103. Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: Results of a 2-year randomized controlled trial (the PROSPECT study). Proscar safety plus efficacy Canadian two year study. CMAJ 1996;155:1251-9.
104. Debruyne FM, Jardin A, Colloi D, Resel L, Witjes WP, Delauche- Cavallier MC, McCarthy C, Geffriaud-Ricouard C. Sustained-release alfuzosin, finasteride and combination of both in the treatment of benign prostatic hyperplasia. European ALFIN study group. Eur Urol 1998;34:169-75.
105. Stoner E. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994;43:284-92.
106. Wessels H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J, PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo treated men with benign prostatic hyperplasia. Urology 2003;61:579-84.
107. Cunningham GR, Hirshkowitz M. Inhibition of steroid 5 alpha-reductase with finasteride: Sleep-related erections, potency, and libido in healthy men. J Clin Endocrinol Metab 1995;80:1934-40.
108. Tosti A, Pazzaglia M, Soli M, Rossi A, Rebora A, Atzori L, Barbareschi M, Benci M, Voudouris S, Vena GA. Evaluation of sexual function with an International Index of Erectile Function in subjects taking finasteride for androgenetic alopecia. Arch Dermatol 2004;140:857-8.
109. Tosti A, Pirracini BM, Soli M. Evaluation of sexual function in subjects taking finasteride for androgenetic alopecia. J Eur Acad Dermatol Venereol 2001;15:418-21.
110. Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, Bartoletti R. Finasteride 5mg and sexual side effects: How many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708-12.
111. Roehrborn CG, Marks LS, Fenter T, Freedman S, Tuttle J, Gittleman M, Morrill B, Wolford ET. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63:709-15.
112. Andriole GL, Kirby R. Safety and tolerability of the dual 5 alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia. Eur Urol 2003;44:82-8.